Focusing on the development of in vitro diagnostic (IVD) reagents for many years, Creative Biolabs is able to offer a full package of IVD antibody development services for the diagnosis of a diversified battery of cancers. Here, we are happy to introduce our high-quality antibody development services against complement factor H (CFH) marker for the diagnosis of bladder cancer.
CFH is a single polypeptide chain plasma glycoprotein (155 kDa) with 20 domains termed complement control protein (CCP) domains or short consensus repeats (SCR). It is a major regulator of the alternative complement pathway (AP). Studies have shown that CFH regulates complement activity by inhibiting the assembly of the AP C3 convertase, by facilitating the disassembly of already formed C3 (C3bBb) and C5 (C3bBb3b) convertases (called decay acceleration activity) or by acting as a cofactor for the complement factor I-mediated degradation of C3b. Furthermore, CFH could act in concert with other regulatory proteins, among them is properdin that acts as an initiator and stabilizer of the AP, membrane cofactor protein (CD46) that acts as a cofactor for complement factor I-mediated cleavage of C3b, and CFHR1 that inhibits the C5 convertase and terminal complement complex.
Fig.1 CFH and related proteins as markers of cardiovascular risk in pediatric chronic kidney disease.1
Bladder cancer, concerning approximately 350,000 new cases each year worldwide, is constantly increasing. During the past years, bladder cancer detection/diagnosis relies on the combination of cystoscopy, voided urine cytology, and CT scan. However, the currently available tools all have caveats. For example, cystoscopy is an invasive procedure and urinary cytology comes with heterogeneity in interpretation among uropathologists, difficulties in interpretation in case of urinary tract infection, and low sensitivity especially for low-grade tumors. Therefore, the routine uses of both sensitive and specific biomarkers that could help in both diagnosis and surveillance settings of bladder cancer will be a challenge for the last decades. Recently, a new bladder-cancer-associated antigen, human complement factor-H-related protein (hcfHrp), has recently been introduced for the detection of bladder cancer. Especially, more and more reports have indicated that CFH could be treated as a specific marker for the detection of bladder cancer.
Detection of CFH in patient biological samples with antibody-based tools can be used for various applications, such as disease screening and therapeutic monitoring. Through our role as a leading IVD antibody development company, Creative Biolabs is dedicated to delivering a full range of IVD development services to global researchers. In addition to CFH marker, we also provide IVD antibody development services against other potential markers.
Creative Biolabs offers high-quality antibodies that are validated for different immuno-techniques, including immunohistochemistry, western blot, ELISA, and flow cytometry. Further, we offer immunoassay development services using high-quality antibodies or antibody pairs for research and diagnostic applications. If you are interested in our IVD antibody development services, please contact us for more details.
Reference
For Research Use Only.
